Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) T.ATE


Primary Symbol: ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Post by Arbourmarkon Mar 30, 2021 8:32am
302 Views
Post# 32904584

Posts

PostsThere are some people who post the same topic continuously every week regarding Nasdaq, to the point they post a new post every 2 minutes. I often wonder if they are talking to themselves.

I have no idea why anyone would feel that up listing to the Nasdaq which required a $4 min share price which we currently do not qualify for as our current value in usd is $3.96 but as mentioned many time previously you do not up list at the bare minimum and that is extremely risky that shirts will knock the price lower and will easily smell blood. There are shorts on the Nasdaq and they are very aggressive. Shorting a stock that barely qualifies will force share price lower thus forcing Nasdaq exchange to notify company that they are in the penalty box which if the share price does not recover in the time frame that the exchange requires they will be delisted or force the company to do another reverse split.

Is that what you want.

Management is clear, this is not the time to uplist to Nasdaq. Management has a plan and is clearly demonstrating that. They have communicated about this a few times that they will be uplisting to Nasdaq when the time is appropriate, most likely the fall.

For anyone to state that Big Pharma is not interested in this company due to sector rotation in general markets is illogical. Big Pharma only invests in the Pharma industry, they are not moving their billions in commodities.

If you are not patient enough to wait 12 more months then this is not the right investment vehicle for you. 
<< Previous
Bullboard Posts
Next >>